Beta-thalassemia: renal complications and mechanisms: a narrative review

References

• Yesilipek MA. Stem cell transplantation in hemoglobinopathies. Hemoglobin. 2007;31:251–256. doi: 10.1080/03630260701297196
   PubMed Web of Science ®Google Scholar
• Rivella S. Beta-thalassemias: paradigmatic diseases for scientific discoveries and development of innovative therapies. Haematologica. 2015;100:418–430. doi: 10.3324/haematol.2014.114827
   PubMed Web of Science ®Google Scholar
• Shinar E, Rachmilewitz EA. Oxidative denaturation of red blood cells in thalassemia. Semin Hematol. 1990;27:70–82.
   PubMed Web of Science ®Google Scholar
• Yuan J, Kannan R, Shinar E, et al. Isolation, characterization, and immunoprecipitation studies of immune complexes from membranes of beta-thalassemic erythrocytes. Blood. 1992;79:3007–3013.
   PubMed Web of Science ®Google Scholar
• Origa R. Beta-thalassemia. Genet Med. 2017;19:609–619. doi: 10.1038/gim.2016.173
   PubMed Web of Science ®Google Scholar
• DeLoughery TG. Microcytic anemia. N Engl J Med. 2014;371:2537. doi: 10.1056/NEJMra1215361
   PubMed Web of Science ®Google Scholar
• Weatherall DJ. The inherited diseases of hemoglobin are an emerging global health burden. Blood. 2010;115:4331–4336. doi: 10.1182/blood-2010-01-251348
   PubMed Web of Science ®Google Scholar
• Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480–487. doi: 10.2471/BLT.06.036673
   PubMed Web of Science ®Google Scholar
• Ginzburg Y, Rivella S. Beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood. 2011;118:4321–4330. doi: 10.1182/blood-2011-03-283614
   PubMed Web of Science ®Google Scholar
• Quinn CT, Johnson VL, Kim HY, et al. Thalassemia clinical research N. renal dysfunction in patients with thalassaemia. Br J Haematol. 2011;153:111–117. doi: 10.1111/j.1365-2141.2010.08477.x
   PubMed Web of Science ®Google Scholar
• Yaghobi M, Miri-Moghaddam E, Majid N, et al. Complications of transfusion-dependent beta-thalassemia patients in Sistan and Baluchistan, South-East of Iran. Int J Hematol Oncol Stem Cell Res. 2017;11:268–272.
   PubMedGoogle Scholar
• Mokhtar GM, Gadallah M, El Sherif NH, et al. Morbidities and mortality in transfusion dependent beta-thalassemia patients (single-center experience). Pediatr Hematol Oncol. 2013;30:93–103. doi: 10.3109/08880018.2012.752054
   PubMed Web of Science ®Google Scholar
• Ong-ajyooth L, Malasit P, Ong-ajyooth S, et al. Renal function in adult beta-thalassemia/Hb E disease. Nephron. 1998;78:156–161. doi: 10.1159/000044904
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh A, Jalali A, Assar S, et al. Renal tubular dysfunction in pediatric patients with beta-thalassemia major. Saudi J Kidney Dis Transpl. 2011;22:497–500.
   PubMedGoogle Scholar
• Sadeghi-Bojd S, Hashemi M, Karimi M. Renal tubular function in patients with beta-thalassaemia major in Zahedan, Southeast Iran. Singapore Med J. 2008;49:410–412.
   PubMed Web of Science ®Google Scholar
• Sen V, Ece A, Uluca U, et al. Urinary early kidney injury molecules in children with beta-thalassemia major. Ren Fail. 2015;37:607–613. doi: 10.3109/0886022X.2015.1007871
   PubMed Web of Science ®Google Scholar
• Patsaoura A, Tatsi E, Margeli A, et al. Plasma neutrophil gelatinase-associated lipocalin levels are markedly increased in patients with non-transfusion-dependent thalassemia: Lack of association with markers of erythropoiesis, iron metabolism and renal function. Clin Biochem. 2014;47:1060–1064. doi: 10.1016/j.clinbiochem.2014.03.017
   PubMed Web of Science ®Google Scholar
• Roudkenar MH, Halabian R, Oodi A, et al. Upregulation of neutrophil gelatinase-associated lipocalin, NGAL/Lcn2, in betathalassemia patients. Arch Med Res. 2008;39:402–407. doi: 10.1016/j.arcmed.2007.12.002
   PubMed Web of Science ®Google Scholar
• Aldudak B, Karabay Bayazit A, Noyan A, et al. Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol. 2000;15:109–112. doi: 10.1007/s004670000434
   PubMed Web of Science ®Google Scholar
• Mohkam M, Shamsian BS, Gharib A, et al. Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol. 2008;23:971–976. doi: 10.1007/s00467-008-0753-x
   PubMed Web of Science ®Google Scholar
• Smolkin V, Halevy R, Levin C, et al. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol. 2008;23:1847–1851. doi: 10.1007/s00467-008-0897-8
   PubMed Web of Science ®Google Scholar
• Sumboonnanonda A, Malasit P, Tanphaichitr VS, et al. Renal tubular function in beta-thalassemia. Pediatr Nephrol. 1998;12:280–283. doi: 10.1007/s004670050453
   PubMed Web of Science ®Google Scholar
• Zhou XJ, Laszik Z, Wang XQ, et al. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest. 2000;80:1905–1914. doi: 10.1038/labinvest.3780200
   PubMed Web of Science ®Google Scholar
• Michelakakis H, Dimitriou E, Georgakis H, et al. Iron overload and urinary lysosomal enzyme levels in beta-thalassaemia major. Eur J Pediatr. 1997;156:602–604. doi: 10.1007/s004310050673
   PubMed Web of Science ®Google Scholar
• Koliakos G, Papachristou F, Koussi A, et al. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol. 2003;25:105–109. doi: 10.1046/j.1365-2257.2003.00507.x
   PubMedGoogle Scholar
• Hashemieh M, Azarkeivan A, Akhlaghpoor S, et al. T2-star (T2*) magnetic resonance imaging for assessment of kidney iron overload in thalassemic patients. Arch Iran Med. 2012;15:91–94.
   PubMed Web of Science ®Google Scholar
• Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17–25. doi: 10.1681/ASN.2005070757
   PubMed Web of Science ®Google Scholar
• Nagababu E, Gulyani S, Earley CJ, et al. Iron-deficiency anaemia enhances red blood cell oxidative stress. Free Radic Res. 2008;42:824–829. doi: 10.1080/10715760802459879
   PubMed Web of Science ®Google Scholar
• Manotham K, Tanaka T, Matsumoto M, et al. Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney Int. 2004;65:871–880. doi: 10.1111/j.1523-1755.2004.00461.x
   PubMed Web of Science ®Google Scholar
• Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int. 2000;58:2351–2366. doi: 10.1046/j.1523-1755.2000.00419.x
   PubMed Web of Science ®Google Scholar
• Norman JT, Orphanides C, Garcia P, et al. Hypoxia-induced changes in extracellular matrix metabolism in renal cells. Exp Nephrol. 1999;7:463–469. doi: 10.1159/000020625
   PubMedGoogle Scholar
• Tantawy AA, El Bablawy N, Adly AA, et al. Early predictors of renal dysfunction in Egyptian patients with beta-thalassemia major and intermedia. Mediterr J Hematol Infect Dis. 2014;6:e2014057. doi: 10.4084/mjhid.2014.057
   PubMedGoogle Scholar
• Sumboonnanonda A, Sanpakit K, Piyaphanee N. Renal tubule function in beta-thalassemia after hematopoietic stem cell transplantation. Pediatr Nephrol. 2009;24:183–187. doi: 10.1007/s00467-008-0949-0
   PubMed Web of Science ®Google Scholar
• Davis LE, Hohimer AR. Hemodynamics and organ blood flow in fetal sheep subjected to chronic anemia. Am J Physiol. 1991;261:R1542–8.
   PubMedGoogle Scholar
• Lafferty HM, Anderson S, Brenner BM. Anemia: a potent modulator of renal hemodynamics in models of progressive renal disease. Am J Kidney Dis. 1991;17:2–7.
   PubMed Web of Science ®Google Scholar
• Hostetter TH. Hyperfiltration and glomerulosclerosis. Semin Nephrol. 2003;23:194–199. doi: 10.1053/snep.2003.50017
   PubMed Web of Science ®Google Scholar
• Alfrey AC. Role of iron and oxygen radicals in the progression of chronic renal failure. Am J Kidney Dis. 1994;23:183–187. doi: 10.1016/S0272-6386(12)80969-3
   PubMed Web of Science ®Google Scholar
• Musallam KM, Taher AT. Mechanisms of renal disease in beta-thalassemia. J Am Soc Nephrol. 2012;23:1299–1302. doi: 10.1681/ASN.2011111070
   PubMed Web of Science ®Google Scholar
• Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am. 1987;34:571–590. doi: 10.1016/S0031-3955(16)36251-4
   PubMed Web of Science ®Google Scholar
• Levey AS, Coresh J, Greene T, et al. Chronic kidney disease epidemiology C. using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247–254. doi: 10.7326/0003-4819-145-4-200608150-00004
   PubMed Web of Science ®Google Scholar
• Milo G, Feige Gross Nevo R, Pazgal I, et al. GFR in patients with beta-thalassemia major. Clin J Am Soc Nephrol. 2015;10:1350–1356. doi: 10.2215/CJN.12181214
   PubMed Web of Science ®Google Scholar
• Economou M, Printza N, Teli A, et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol. 2010;123: 148–152. doi: 10.1159/000287238
   PubMed Web of Science ®Google Scholar
• Hamed EA, ElMelegy NT. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Ital J Pediatr. 2010;36:39. doi: 10.1186/1824-7288-36-39
   PubMed Web of Science ®Google Scholar
• Al-Khabori M, Bhandari S, Al-Rasadi K, et al. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with thalassemia major. Haemoglobin. 2014;38:365–368. doi: 10.3109/03630269.2014.944314
   PubMed Web of Science ®Google Scholar
• Piga A, Fracchia S, Lai ME, et al. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent beta thalassaemia. Br J Haematol. 2015;168:882–890. doi: 10.1111/bjh.13217
   PubMed Web of Science ®Google Scholar
• Lai ME, Spiga A, Vacquer S. Renal function in patients with β-thalassaemia major: a long-term follow-up study. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2012;27(9):3547–3598. doi: 10.1093/ndt/gfs169
   PubMed Web of Science ®Google Scholar
• Deveci B, Kurtoglu A, Kurtoglu E, et al. Documentation of renal glomerular and tubular impairment and glomerular hyperfiltration in multitransfused patients with beta thalassemia. Ann Hematol. 2016;95:375–381. doi: 10.1007/s00277-015-2561-2
   PubMed Web of Science ®Google Scholar
• Shapira Y, Glick B, Finsterbush A, et al. Myopathological findings in thalassemia major. Eur Neurol. 1990;30: 324–327. doi: 10.1159/000117365
   PubMed Web of Science ®Google Scholar
• Logothetis J, Constantoulakis M, Economidou J, et al. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology. 1972;22:294–304. doi: 10.1212/WNL.22.3.294
   PubMed Web of Science ®Google Scholar
• Levey AS. Measurement of renal function in chronic renal disease. Kidney Int. 1990;38:167–184. doi: 10.1038/ki.1990.182
   PubMed Web of Science ®Google Scholar
• Shemesh O, Golbetz H, Kriss JP, et al. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int. 1985;28:830–838. doi: 10.1038/ki.1985.205
   PubMed Web of Science ®Google Scholar
• Hankins DA, Babb AL, Uvelli DA, et al. Creatinine degradation I: the kinetics of creatinine removal in patients with chronic kidney disease. Int J Artif Organs. 1981;4:35–39. doi: 10.1177/039139888100400209
   PubMed Web of Science ®Google Scholar
• Moore AE, Park-Holohan SJ, Blake GM, et al. Conventional measurements of GFR using 51Cr-EDTA overestimate true renal clearance by 10 percent. Eur J Nucl Med Mol Imaging. 2003;30:4–8. doi: 10.1007/s00259-002-1007-y
   PubMed Web of Science ®Google Scholar
• Filler G, Huang SH, Yasin A. The usefulness of cystatin C and related formulae in pediatrics. Clin Chem Lab Med. 2012;50:2081–2091. doi: 10.1515/cclm-2012-0257
   PubMed Web of Science ®Google Scholar
• Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis. 2002;40:221–226. doi: 10.1053/ajkd.2002.34487
   PubMed Web of Science ®Google Scholar
• Stevens LA, Coresh J, Schmid CH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008;51:395–406. doi: 10.1053/j.ajkd.2007.11.018
   PubMed Web of Science ®Google Scholar
• Rigalleau V, Beauvieux MC, Lasseur C, et al. The combination of cystatin C and serum creatinine improves the monitoring of kidney function in patients with diabetes and chronic kidney disease. Clin Chem. 2007;53:1988–1989. doi: 10.1373/clinchem.2007.092171
   PubMed Web of Science ®Google Scholar
• Skorecki K, Chertow GM, Marsden PA, et al. Brenner & Rector's the kidney. 10th ed. Elsevier; 2015.
   Google Scholar
• Ali D, Mehran K, Moghaddam AG. Comparative evaluation of renal findings in beta-thalassemia major and intermedia. Saudi J Kidney Dis Transpl. 2008;19:206–209.
   PubMedGoogle Scholar
• Fallahzadeh MH, Fallahzadeh MK, Shahriari M, et al. Hematuria in patients with beta-thalassemia major. Iran J Kidney Dis. 2010;4:133–136.
   PubMed Web of Science ®Google Scholar
• Wong P, Milat F, Fuller PJ, et al. Urolithiasis is prevalent and associated with reduced bone mineral density in betathalassaemia major. Intern Med J. 2017;47:1064–1067. doi: 10.1111/imj.13533
   PubMed Web of Science ®Google Scholar
• Wong P, Fuller PJ, Gillespie MT, et al. Thalassemia bone disease: the association between nephrolithiasis, bone mineral density and fractures. Osteoporos Int. 2013;24:1965–1971. doi: 10.1007/s00198-012-2260-y
   PubMed Web of Science ®Google Scholar
• Heaney RP. Calcium supplementation and incident kidney stone risk: a systematic review. J Am Coll Nutr. 2008;27:519–527. doi: 10.1080/07315724.2008.10719734
   PubMed Web of Science ®Google Scholar
• Malihi Z, Wu Z, Stewart AW, et al. Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr. 2016;104:1039–1051. doi: 10.3945/ajcn.116.134981
   PubMed Web of Science ®Google Scholar
• Ricchi P, Ammirabile M, Costantini S, et al. Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: a retrospective study. Blood Cells Mol Dis. 2012;49:133–135. doi: 10.1016/j.bcmd.2012.05.012
   PubMed Web of Science ®Google Scholar
• Papassotiriou I, Margeli A, Hantzi E, et al. Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis. 2010;44:152–155. doi: 10.1016/j.bcmd.2010.01.001
   PubMed Web of Science ®Google Scholar
• Ponticelli C, Musallam KM, Cianciulli P, et al. Renal complications in transfusiondependent beta thalassaemia. Blood Rev. 2010;24:239–244. doi: 10.1016/j.blre.2010.08.004
   PubMed Web of Science ®Google Scholar
• Hoffbrand AV, Faris AL-R, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood. 1998;91:295–300.
   PubMed Web of Science ®Google Scholar
• ElAlfy MS, Sari TT, Lee CL, et al. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload. J Pediatr Hematol Oncol. 2010;32:601–605. doi: 10.1097/MPH.0b013e3181ec0f13
   PubMed Web of Science ®Google Scholar
• Bragadesh T, Bhandari S. The use of deferiprone, iron overload in a renal transplant patient. Q J Med. 2014;107:465–466. doi: 10.1093/qjmed/hct254
   Google Scholar
• Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102:17–24. doi: 10.1182/blood-2002-06-1867
   PubMed Web of Science ®Google Scholar
• De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood. 2009;114:4546–4551. doi: 10.1182/blood-2009-05-224188
   PubMed Web of Science ®Google Scholar
• Bhandari S, Galanello R. Renal aspects of thalassaemia a changing paradigm. Eur J Haematol. 2012;89:187–197. doi: 10.1111/j.1600-0609.2012.01819.x
   PubMed Web of Science ®Google Scholar
• Chuang GT, Tsai IJ, Tsau YK, et al. Transfusion-dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use. Nephrology. 2015;20:931–935. doi: 10.1111/nep.12523
   PubMed Web of Science ®Google Scholar
• Dee CM, Cheuk DK, Ha SY, et al. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia. Br J Haematol. 2014;167:434–436. doi: 10.1111/bjh.13002
   PubMed Web of Science ®Google Scholar
• Dell'Orto VG, Bianchetti MG, Brazzola P. Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature. J Clin Pharm Ther. 2013;38:526–527. doi: 10.1111/jcpt.12095
   PubMed Web of Science ®Google Scholar
• Even-Or E, Becker-Cohen R, Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol. 2010;85:132–134.
   PubMed Web of Science ®Google Scholar
• Grange S, Bertrand DM, Guerrot D, et al. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant. 2010;25:2376–2378. doi: 10.1093/ndt/gfq224
   PubMed Web of Science ®Google Scholar
• Murphy N, Elramah M, Vats H, et al. A case report of deferasirox-induced kidney injury and Fanconi syndrome. WMJ. 2013;112:177–180.
   PubMedGoogle Scholar
• Papadopoulos N, Vasiliki A, Aloizos G, et al. Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major. Ann Pharmacother. 2010;44:219–221. doi: 10.1345/aph.1M440
   PubMed Web of Science ®Google Scholar
• Rafat C, Fakhouri F, Ribeil JA, et al. Fanconi syndrome due to deferasirox. Am J Kidney Dis. 2009;54:931–934. doi: 10.1053/j.ajkd.2009.03.013
   PubMed Web of Science ®Google Scholar
• Rheault MN, Bechtel H, Neglia JP, et al. Reversible Fanconi syndrome in a pediatric patient on deferasirox. Pediatr Blood Cancer. 2011;56:674–676. doi: 10.1002/pbc.22711
   PubMed Web of Science ®Google Scholar
• Wei HY, Yang CP, Cheng CH, et al. Fanconi syndrome in a patient with beta-thalassemia major after using deferasirox for 27 months. Transfusion. 2011;51:949–954. doi: 10.1111/j.1537-2995.2010.02939.x
   PubMed Web of Science ®Google Scholar
• Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in beta-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010;32:564–567. doi: 10.1097/MPH.0b013e3181ec0c38
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107: 3455–3462. doi: 10.1182/blood-2005-08-3430
   PubMed Web of Science ®Google Scholar
• Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood. 2011;118:884–893. doi: 10.1182/blood-2010-11-316646
   PubMed Web of Science ®Google Scholar
• Papneja K, Bhatt MD, Kirby-Allen M, et al. Fanconi syndrome secondary to deferasirox in Diamond-Blackfan anemia: case Series and Recommendations for early diagnosis. Pediatr Blood Cancer. 2016;63:1480–1483. doi: 10.1002/pbc.25995
   PubMed Web of Science ®Google Scholar
• Tunc B, Tavil B, Karakurt N, et al. Deferasirox therapy in children with Fanconi aplastic anemia. J Pediatr Hematol Oncol. 2012;34:247–251. doi: 10.1097/MPH.0b013e318249a4be
   PubMed Web of Science ®Google Scholar
• Shah L, Powell JL, Zaritsky JJ. A case of Fanconi syndrome due to a deferasirox overdose and a trial of plasmapheresis. J Clin Pharm Ther. 2017;42:634–637. doi: 10.1111/jcpt.12553
   PubMed Web of Science ®Google Scholar
• Wong P, Polkinghorne K, Kerr PG, et al. Deferasirox at therapeutic doses is associated with dose-dependent hypercalciuria. Bone. 2016;85:55–58. doi: 10.1016/j.bone.2016.01.011
   PubMed Web of Science ®Google Scholar
• Efthimia V, Neokleous N, Agapidou A, et al. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience. Ann Hematol. 2013;92:263–265. doi: 10.1007/s00277-012-1558-3
   PubMed Web of Science ®Google Scholar
• Al-Khabori M, Bhandari S, Al-Huneini M, et al. Side effects of deferasirox iron chelation in patients with beta thalassemia major or intermedia. Oman Med J. 2013;2:121–124. doi: 10.5001/omj.2013.31
   Google Scholar
• Beydoun HG, Saliba AN, Taher AT. Deferasirox in thalassemia patients with end-stage renal disease. Am J Hematol. 2016;91:E456–E457. doi: 10.1002/ajh.24457
   PubMed Web of Science ®Google Scholar
• Karimi M, Avazpour A, Haghpanah S, et al. Evaluation of proteinuria in beta- thalassemia major patients With and without diabetes mellitus Taking deferasirox. J Pediatr Hematol Oncol. 2017;39:e11–ee4. doi: 10.1097/MPH.0000000000000658
   PubMed Web of Science ®Google Scholar
• Brittenham GM. Iron-chelating therapy for transfusional iron overload. N Engl J Med. 2011;364:146–156. doi: 10.1056/NEJMct1004810
   PubMed Web of Science ®Google Scholar
• Prasannan L, Flynn JT, Levine JE. Acute renal failure following deferoxamine overdose. Pediatr Nephrol. 2003;18:283–285.
   PubMed Web of Science ®Google Scholar
• Aydinok Y, Coker C, Kavakli K, et al. Urinary zinc excretion and zinc status of patients with beta-thalassemia major. Biol Trace Elem Res. 1999;70:165–172. doi: 10.1007/BF02783857
   PubMed Web of Science ®Google Scholar
• Adamkiewicz TV, Berkovitch M, Krishnan C, et al. Infection due to Yersinia enterocolitica in a series of patients with beta-thalassemia: incidence and predisposing factors. Clin Infect Dis. 1998;27:1362–1366. doi: 10.1086/515025
   PubMed Web of Science ®Google Scholar
• Chan GC, Chan S, Ho PL, et al. Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusiondependent thalassemia patients. Hemoglobin. 2009;33:352–360. doi: 10.3109/03630260903211888
   PubMed Web of Science ®Google Scholar
• Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest. 1993;91:1979–1986. doi: 10.1172/JCI116419
   PubMed Web of Science ®Google Scholar
• Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol. 2008;83:398–402. doi: 10.1002/ajh.21119
   PubMed Web of Science ®Google Scholar